Alogliptin Benzoate Powder Anti-diabetic Drug Medical Grade for Type 2 Diabetes
What is Alogliptin?
Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). Antidiabetic agent.Alogliptin is an orally administered anti-diabetic drug in the DPP-4 inhibitor class, Like other medications for the treatment of Type 2 diabetes, alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of causing hypoglycemia, and exhibits relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone.
Alogliptin Benzoate Certificate of Analysis
| Product name |
Alogliptin benzoate |
| CAS No. |
850649-62-6 |
Outer Packing |
1kg/bag |
| Production date |
Jan 20th 2018 |
Shelf life |
2 years |
| Standard adopted |
Enterprise Standard |
| Item |
Specifications |
Results |
| Appearance |
White or white crystalline powder |
white crystalline powder |
| Identification |
Retention time should be consistent with the reference substance |
complies |
| Heavy metals |
≤10ppm
Maximum≤10ppm |
complies |
| Loss on drying |
Not exceed 0.50% |
0.15% |
| Melting point |
Should be 126–131°C |
126–128°C |
| Total impurities |
Not exceed 0.3% |
0.09% |
| Related compound A |
Not exceed 0.10% |
0.05% |
| Any unspecified impurity |
Any unspecified impurity:Not exceed 0.10% |
Complies |
| Enantiomers |
Not detected |
Not detected |
| Residue on ignition |
NMT 0.1% |
Complies |
| Assay |
NLT 98.0% and NMT 102.0%, calculated on the dried basis |
99.8% |
| Conclusion |
Complies |
Alogliptin Benzoate Side Effects
Adverse events include mild hypoglycemia based on clinical studies. Alogliptin is not associated with increased weight, increased risk of cardiovasular events. It may also cause joint pain that can be severe and disabling.
In April 2016, the U.S. FDA added a warning about increased risk of heart failure.
